GentiBio
Rachel Yost is an Associate Director, MSAT at GentiBio. Prior to joining GentiBio, Rachel worked at Juno Therapeutics / Bristol Myers Squibb, playing a significant role in Global Manufacturing, Science & Technology (MSAT) throughout the lifecycle of the Breyanzi CAR-T cell therapy product. Most recently Rachel lead the MSAT Early Phase Drug Product Stewardship team supporting multiple pipeline cell therapy programs. Rachel was previously a process engineer at Merck in Durham, NC. Rachel received her BS in Bioengineering from Penn State.
This person is not in any offices
GentiBio
GentiBio, Inc., is an early stage biotherapeutics company co-founded by pioneers in Treg biology and synthetic immunology to develop engineered regulatory T cells (EngTregs) programmed to treat autoimmune, alloimmune, autoinflammatory and allergic diseases. GentiBio's proprietary autologous and allogeneic EngTregs platform integrates key complimentary technologies needed to successfully restore immune tolerance and overcome major limitations in existing regulatory T-cell therapeutics. GentiBio is at the forefront of leveraging a unique therapeutic modality that can be used to address the fundamental cause of many diseases that result from overshooting and/or malfunctioning of the immune system.